273 related articles for article (PubMed ID: 23636648)
1. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis.
Elting LS; Chang YC; Parelkar P; Boers-Doets CB; Michelet M; Hita G; Rouleau T; Cooksley C; Halm J; Vithala M; Bossi P; Escalante C; Brennan MT;
Support Care Cancer; 2013 Nov; 21(11):3243-54. PubMed ID: 23636648
[TBL] [Abstract][Full Text] [Related]
2. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.
Escalante CP; Chang YC; Liao K; Rouleau T; Halm J; Bossi P; Bhadriraju S; Brito-Dellan N; Sahai S; Yusuf SW; Zalpour A; Elting LS;
Support Care Cancer; 2016 Sep; 24(9):4057-74. PubMed ID: 27344327
[TBL] [Abstract][Full Text] [Related]
4. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Abdel-Rahman O; ElHalawani H; Essam-Eldin S
Expert Opin Drug Saf; 2016 Jan; 15(1):5-20. PubMed ID: 26513339
[TBL] [Abstract][Full Text] [Related]
5. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.
Trotti A; Bellm LA; Epstein JB; Frame D; Fuchs HJ; Gwede CK; Komaroff E; Nalysnyk L; Zilberberg MD
Radiother Oncol; 2003 Mar; 66(3):253-62. PubMed ID: 12742264
[TBL] [Abstract][Full Text] [Related]
6. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
7. New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies.
Li E; Trovato JA
Am J Health Syst Pharm; 2012 Jun; 69(12):1031-7. PubMed ID: 22644979
[TBL] [Abstract][Full Text] [Related]
8. Prevention of oral mucositis or oral candidiasis for patients with cancer receiving chemotherapy (excluding head and neck cancer).
Clarkson JE; Worthington HV; Eden OB
Cochrane Database Syst Rev; 2000; (2):CD000978. PubMed ID: 10796567
[TBL] [Abstract][Full Text] [Related]
9. Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Worthington HV; Clarkson JE; Eden OB
Cochrane Database Syst Rev; 2006 Apr; (2):CD000978. PubMed ID: 16625538
[TBL] [Abstract][Full Text] [Related]
10. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials.
Miroddi M; Sterrantino C; Simonelli I; Ciminata G; Phillips RS; Calapai G
Crit Rev Oncol Hematol; 2015 Nov; 96(2):355-71. PubMed ID: 26160607
[TBL] [Abstract][Full Text] [Related]
11. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy.
Okada T; Nakajima Y; Nishikage T; Ryotokuji T; Miyawaki Y; Hoshino A; Tokairin Y; Kawada K; Nagai K; Kawano T
Asia Pac J Clin Nutr; 2017 Jan; 26(1):42-48. PubMed ID: 28049260
[TBL] [Abstract][Full Text] [Related]
13. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
14. Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Worthington HV; Clarkson JE; Eden OB
Cochrane Database Syst Rev; 2007 Oct; (4):CD000978. PubMed ID: 17943748
[TBL] [Abstract][Full Text] [Related]
15. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases.
Raber-Durlacher JE; Weijl NI; Abu Saris M; de Koning B; Zwinderman AH; Osanto S
Support Care Cancer; 2000 Sep; 8(5):366-71. PubMed ID: 10975685
[TBL] [Abstract][Full Text] [Related]
16. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
17. Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Clarkson JE; Worthington HV; Eden OB
Cochrane Database Syst Rev; 2003; (3):CD000978. PubMed ID: 12917895
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial.
Bentzen SM; Saunders MI; Dische S; Bond SJ
Radiother Oncol; 2001 Aug; 60(2):123-35. PubMed ID: 11439207
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy-induced stomatitis and diarrhea].
Kadowaki S; Yamaguchi K
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1761-6. PubMed ID: 22083181
[TBL] [Abstract][Full Text] [Related]
20. Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Porta C; Gore ME; Rini BI; Escudier B; Hariharan S; Charles LP; Yang L; DeAnnuntis L; Motzer RJ
Eur Urol; 2016 Feb; 69(2):345-51. PubMed ID: 26215605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
